data_1s7p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1s7p _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.452 -0.356 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 C--O 1.233 0.225 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 120.752 0.311 . . . . 0.0 110.715 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.44 0 CA-C-O 120.692 0.282 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . 0.489 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.42 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.42 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.489 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo . . . . . 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.421 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.427 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo . . . . . 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.924 0.392 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo . . . . . 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.81 0.338 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.429 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.0 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 110.72 -0.104 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . 0.477 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.477 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.451 -0.388 0 CA-C-O 120.593 0.235 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . 0.498 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.498 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo . . . . . 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.453 -0.312 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.42 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.42 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo . . . . . 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 110.394 -0.225 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . 0.473 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.473 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo . . . . . 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.453 -0.293 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.424 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.424 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo . . . . . 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 110.517 -0.179 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo . . . . . 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.684 0.278 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo . . . . . 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 110.646 -0.131 . . . . 0.0 110.646 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.447 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.234 0.271 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo . . . . . 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.451 -0.411 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . 0.485 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.485 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.479 ' HD2' HG13 ' A' ' 6' ' ' VAL . 34.8 Cg_endo . . . . . 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.532 0.205 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo . . . . . 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 4.0 t . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.297 0.57 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . 0.54 ' HA2' HD12 ' B' ' 17' ' ' ILE . . . 72.62 -70.33 1.14 Allowed Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.398 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 12.1 tt -71.7 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 33.75 85.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.079 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 11.7 m -127.79 130.77 23.61 Favored Pre-proline 0 C--N 1.319 -0.74 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.13 60.46 3.14 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 123.129 2.552 . . . . 0.0 112.983 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.54 HD12 ' HA2' ' B' ' 12' ' ' GLY . 33.9 mt -60.51 141.37 17.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.155 0.502 . . . . 0.0 110.179 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p -160.4 -159.85 0.73 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.964 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -70.52 121.04 7.59 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -92.72 62.58 3.8 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.077 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -79.81 143.38 34.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.251 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.197 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.414 ' H1 ' ' C ' ' A' ' 10' ' ' PHE . 7.3 p . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.75 -60.94 3.71 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 -178.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.9 tt -95.68 125.6 48.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.2 -65.45 3.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.209 -0.519 . . . . 0.0 112.552 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.0 p -98.33 133.97 22.37 Favored Pre-proline 0 C--N 1.317 -0.842 0 CA-C-O 120.675 0.274 . . . . 0.0 110.611 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.529 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 68.8 Cg_endo -74.63 -131.88 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.889 2.393 . . . . 0.0 113.135 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.529 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 11.8 tt -165.24 153.73 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.813 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p -158.39 -170.5 3.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.508 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.455 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.45 123.82 10.94 Favored 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.455 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.6 pt-20 -104.75 58.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.99 178.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.431 ' HB3' HG13 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -80.82 146.88 30.7 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.517 -179.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.414 ' C ' ' H1 ' ' B' ' 11' ' ' VAL . 26.0 t80 . . . . . 0 C--O 1.247 0.925 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.476 0.845 0 CA-C-O 120.923 0.392 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.45 140.42 5.01 Favored Glycine 0 N--CA 1.445 -0.765 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 61.4 mt -64.91 111.15 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.05 -39.52 1.06 Allowed Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.674 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 1.9 m -77.4 124.9 86.87 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.608 -0.296 . . . . 0.0 110.667 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.29 118.0 5.34 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.614 2.209 . . . . 0.0 111.837 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.5 pt -77.11 148.5 6.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.675 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -155.14 177.83 10.89 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.429 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -65.52 133.87 36.21 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.429 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.1 pt-20 -108.46 55.68 0.64 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.245 0.545 . . . . 0.0 110.599 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 30.4 t80 -160.81 156.64 25.48 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.014 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.6 t80 . . . . . 0 C--O 1.25 1.1 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.688 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.484 ' H1 ' ' C ' ' A' ' 10' ' ' PHE . 22.7 m . . . . . 0 N--CA 1.479 1.014 0 CA-C-O 120.724 0.297 . . . . 0.0 110.57 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.4 -111.79 4.04 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.458 -0.877 . . . . 0.0 111.907 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 10.9 tt -62.19 131.63 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.618 0.247 . . . . 0.0 110.619 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.8 -48.38 85.52 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.952 -179.05 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' THR . . . . . 0.405 ' O ' HG13 ' B' ' 17' ' ' ILE . 17.2 m 71.05 132.94 0.04 OUTLIER Pre-proline 0 CA--C 1.538 0.494 0 O-C-N 123.897 0.41 . . . . 0.0 111.49 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.58 56.04 2.74 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.227 2.618 . . . . 0.0 112.32 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' A' ' 9' ' ' TYR . 2.1 pp -78.95 157.77 4.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.054 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p -88.59 -166.81 1.69 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.731 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.712 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.42 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.42 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.489 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo -65.37 139.23 58.67 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.712 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 26.8 mt-10 -83.75 56.08 3.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.189 0.518 . . . . 0.0 110.067 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.56 ' CB ' HG12 ' B' ' 17' ' ' ILE . 64.9 t80 -160.71 155.08 23.34 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.509 -0.768 . . . . 0.0 110.939 -178.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.484 ' C ' ' H1 ' ' B' ' 11' ' ' VAL . 91.2 m-85 . . . . . 0 C--O 1.247 0.946 0 CA-C-N 114.955 -1.02 . . . . 0.0 108.562 178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.549 ' H3 ' ' C ' ' A' ' 10' ' ' PHE . 46.6 t . . . . . 0 N--CA 1.479 1.0 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . 0.419 ' HA3' ' HE1' ' A' ' 10' ' ' PHE . . . -73.84 142.68 31.23 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.683 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 2.4 pp -74.42 141.4 16.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.719 0.295 . . . . 0.0 110.292 179.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 -44.16 3.12 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.178 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 19.9 m -147.2 120.33 4.88 Favored Pre-proline 0 C--N 1.317 -0.836 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -56.66 -47.05 25.52 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 123.207 2.605 . . . . 0.0 113.841 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.58 HD13 ' H ' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -123.32 147.84 27.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.006 0.431 . . . . 0.0 111.096 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -136.96 -175.33 4.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.742 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.465 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.421 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.421 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.427 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo -64.82 137.82 55.27 Favored 'Trans proline' 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.465 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 3.6 pt-20 -130.36 75.87 1.68 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.188 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.528 ' CD1' HG21 ' B' ' 17' ' ' ILE . 40.4 t80 -79.13 147.91 32.55 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.62 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' H3 ' ' B' ' 11' ' ' VAL . 0.3 OUTLIER . . . . . 0 C--N 1.311 -1.089 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.9 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.503 ' HA ' ' OH ' ' A' ' 9' ' ' TYR . 10.6 p . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.83 -144.38 4.19 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.155 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 20.2 pt -77.26 49.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.115 0.483 . . . . 0.0 111.799 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.61 120.09 0.5 Allowed Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.0 p -131.82 65.11 74.91 Favored Pre-proline 0 C--N 1.319 -0.72 0 N-CA-C 111.436 0.162 . . . . 0.0 111.436 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.8 -38.93 12.47 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.522 2.148 . . . . 0.0 111.869 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 37.8 mm 71.36 142.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.379 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p -161.9 169.24 21.56 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.311 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.454 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.409 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo -65.14 135.81 45.18 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.454 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.3 pt-20 -115.67 56.78 0.75 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.998 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.503 ' OH ' ' HA ' ' B' ' 11' ' ' VAL . 51.3 t80 -160.7 154.3 22.25 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.149 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.3 p90 . . . . . 0 C--O 1.253 1.285 0 CA-C-O 117.655 -1.164 . . . . 0.0 108.844 179.546 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.476 0.861 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.69 -113.17 0.28 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 19.6 mt -75.4 65.09 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.153 0.502 . . . . 0.0 110.371 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.92 -40.88 2.33 Favored Glycine 0 C--N 1.33 0.203 0 CA-C-N 116.009 -0.542 . . . . 0.0 112.971 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' THR . . . . . 0.692 ' HB ' HG12 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -67.01 135.5 94.05 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-O 121.158 0.504 . . . . 0.0 112.097 -179.678 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.55 -25.0 41.38 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 123.238 2.625 . . . . 0.0 112.314 -179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.692 HG12 ' HB ' ' B' ' 15' ' ' THR . 28.8 pt -58.84 158.16 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.826 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.65 168.74 18.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.386 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.405 ' HD2' ' CG ' ' A' ' 8' ' ' GLU . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.429 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.583 ' HB3' HD12 ' B' ' 17' ' ' ILE . 17.0 Cg_exo -67.77 140.22 50.4 Favored 'Trans proline' 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.405 ' CG ' ' HD2' ' B' ' 20' ' ' TYR . 49.9 mt-10 -83.49 53.11 2.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.346 0.593 . . . . 0.0 110.071 178.778 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -160.83 154.79 22.66 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.942 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 . . . . . 0 C--O 1.245 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.063 179.639 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.487 HG12 ' HA2' ' A' ' 1' ' ' GLY . 12.3 p . . . . . 0 N--CA 1.479 0.977 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 71.65 -120.39 8.15 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.678 -179.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.6 tp -61.62 144.32 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.083 0.468 . . . . 0.0 111.4 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.74 -57.73 5.04 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.398 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.1 m -157.5 113.53 1.87 Allowed Pre-proline 0 C--N 1.315 -0.895 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.46 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 26.6 Cg_exo -63.34 -55.49 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.882 2.388 . . . . 0.0 112.315 -179.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 6.1 tt -71.9 137.87 22.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.337 0.589 . . . . 0.0 110.846 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p -161.79 -167.6 1.73 Allowed 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.339 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.42 ' HD2' ' CG ' ' A' ' 8' ' ' GLU . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.487 ' HA2' HG12 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.401 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo -65.93 137.6 49.53 Favored 'Trans proline' 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.42 ' CG ' ' HD2' ' B' ' 20' ' ' TYR . 46.1 mt-10 -80.43 58.01 3.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.449 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -79.99 154.66 28.08 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.526 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.251 1.18 0 CA-C-O 117.547 -1.216 . . . . 0.0 109.382 179.605 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.725 HG21 ' HA2' ' A' ' 1' ' ' GLY . 35.9 m . . . . . 0 N--CA 1.481 1.108 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.23 -145.17 37.28 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.646 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 18.4 pt -83.35 52.78 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.923 0.392 . . . . 0.0 111.919 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.29 -128.79 0.97 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.743 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 21.2 p -82.4 133.7 49.71 Favored Pre-proline 0 C--N 1.315 -0.922 0 CA-C-O 120.573 0.225 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.426 ' O ' HG13 ' B' ' 11' ' ' VAL . 18.2 Cg_endo -59.66 -53.07 3.64 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.477 2.118 . . . . 0.0 110.82 179.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 20.5 mt -75.42 141.48 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -161.51 -163.28 0.97 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.72 -179.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.548 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.725 ' HA2' HG21 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.477 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo -66.74 140.3 55.57 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.548 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 49.2 mt-10 -83.58 55.82 3.36 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.089 178.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -160.95 157.81 27.04 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.967 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.1 t80 . . . . . 0 C--O 1.251 1.166 0 CA-C-O 117.403 -1.284 . . . . 0.0 108.542 179.591 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' B' ' 16' ' ' PRO . 18.9 m . . . . . 0 N--CA 1.477 0.911 0 CA-C-O 120.645 0.259 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.4 -132.54 12.71 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.849 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 16.1 tt -66.5 149.1 11.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.048 0.451 . . . . 0.0 111.601 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.21 -54.42 4.87 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.993 -0.548 . . . . 0.0 112.442 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 83.2 m -157.98 119.99 2.02 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.463 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 34.8 Cg_endo -66.15 -36.03 30.66 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.731 2.288 . . . . 0.0 112.291 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.401 HG21 ' O ' ' A' ' 8' ' ' GLU . 6.1 mt -64.92 161.61 2.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.059 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p -79.34 -165.8 0.84 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.127 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.713 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.411 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.498 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -62.76 142.4 88.89 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.713 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 43.4 mt-10 -80.11 56.38 2.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.313 0.578 . . . . 0.0 110.901 179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -79.14 151.87 31.07 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.824 . . . . 0.0 111.289 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.9 t80 . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.388 -1.292 . . . . 0.0 108.576 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.493 ' HB ' ' HA ' ' B' ' 18' ' ' SER . 20.6 m . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.31 -71.87 1.47 Allowed Glycine 0 N--CA 1.453 -0.218 0 N-CA-C 111.827 -0.509 . . . . 0.0 111.827 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.4 HD11 HG23 ' B' ' 13' ' ' ILE . 50.4 mm -77.68 117.83 23.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 178.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 62.35 21.36 62.07 Favored Glycine 0 C--O 1.226 -0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 113.451 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -161.1 122.24 1.65 Allowed Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.605 0.203 . . . . 0.0 110.56 179.561 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -60.85 -44.19 26.88 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.64 2.227 . . . . 0.0 111.935 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.449 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 41.0 pt -67.08 139.18 21.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.774 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' SER . . . . . 0.493 ' HA ' ' HB ' ' B' ' 11' ' ' VAL . 3.0 p -158.49 -167.81 2.26 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.179 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.408 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -68.16 138.33 43.14 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.408 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.9 mt-10 -81.47 58.22 3.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.051 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -79.68 154.55 28.54 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.623 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.252 1.184 0 CA-C-O 117.485 -1.245 . . . . 0.0 109.377 179.676 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.85 -134.89 3.19 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.526 -0.63 . . . . 0.0 111.526 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.808 HD12 ' H ' ' B' ' 13' ' ' ILE . 0.2 OUTLIER -77.3 58.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.346 0.593 . . . . 0.0 111.014 179.345 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.0 -25.18 27.98 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.045 -179.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' THR . . . . . 0.447 ' HB ' ' HE1' ' B' ' 19' ' ' PHE . 8.3 p -66.54 122.22 80.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 120.998 0.428 . . . . 0.0 111.572 -179.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 16.6 Cg_exo -67.98 -52.36 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.89 2.393 . . . . 0.0 111.998 -179.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.651 ' HB ' ' CE1' ' A' ' 9' ' ' TYR . 39.9 pt -74.24 162.28 4.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.659 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.53 157.46 18.61 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.447 ' HE1' ' HB ' ' B' ' 15' ' ' THR . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.421 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.42 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.42 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.408 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo -62.84 141.5 84.95 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.421 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 50.8 mt-10 -80.0 54.88 1.99 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.077 0.465 . . . . 0.0 110.742 179.371 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.651 ' CE1' ' HB ' ' B' ' 17' ' ' ILE . 62.6 m-85 -143.25 155.18 44.43 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.984 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.5 p90 . . . . . 0 C--O 1.252 1.193 0 CA-C-O 117.447 -1.263 . . . . 0.0 109.207 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.577 ' HA ' ' O ' ' A' ' 1' ' ' GLY . 57.3 t . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.37 -85.71 0.25 Allowed Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 51.3 mm -72.85 125.81 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 178.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.64 39.85 90.49 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.26 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 55.5 m -154.18 120.42 2.79 Favored Pre-proline 0 C--N 1.319 -0.752 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.458 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 85.4 Cg_endo -83.16 -138.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.753 2.302 . . . . 0.0 112.302 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.458 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 32.3 pt -58.95 135.61 23.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.046 0.45 . . . . 0.0 110.48 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p -160.24 -159.95 0.75 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.394 -178.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.574 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.417 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.577 ' O ' ' HA ' ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.417 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.473 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -62.67 140.11 79.03 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.574 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 7.3 mt-10 -80.79 56.92 2.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.305 0.574 . . . . 0.0 110.812 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -79.58 150.93 30.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.029 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 18.3 t80 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.983 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.25 -61.95 4.1 Favored Glycine 0 C--O 1.227 -0.295 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 41.4 mm -82.09 155.39 4.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.44 -36.55 53.81 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.987 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 2.4 p -73.41 144.96 84.64 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-O 120.95 0.405 . . . . 0.0 110.922 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.85 44.27 0.5 Allowed 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 123.176 2.584 . . . . 0.0 113.282 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.476 HG22 ' H ' ' A' ' 10' ' ' PHE . 40.5 pt -61.16 143.38 14.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 CA-C-O 120.98 0.419 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p -159.05 -153.68 0.38 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.571 -0.741 . . . . 0.0 109.89 -178.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.424 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.424 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo -70.09 128.45 15.74 Favored 'Trans proline' 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -105.8 75.73 1.14 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.447 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.4 t80 -77.21 154.58 32.93 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.951 -178.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.476 ' H ' HG22 ' B' ' 17' ' ' ILE . 25.7 t80 . . . . . 0 C--O 1.245 0.825 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.412 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 31.3 t . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 71.99 -118.7 7.05 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.696 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.485 ' H ' HD11 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -62.92 136.32 26.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.974 0.416 . . . . 0.0 110.668 179.333 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 35.73 82.55 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.299 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 73.4 m -156.55 126.81 3.37 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.411 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 91.3 Cg_endo -82.34 -148.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.479 2.119 . . . . 0.0 111.793 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.411 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 7.1 tt -66.33 139.92 20.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.245 0.545 . . . . 0.0 110.494 179.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -157.74 -168.54 2.57 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.517 -179.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.403 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -67.02 139.72 52.05 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 48.0 mt-10 -81.15 55.3 2.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.251 0.548 . . . . 0.0 110.489 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -160.92 156.5 25.01 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.994 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--O 1.246 0.909 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.665 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 45.7 t . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.12 -119.59 7.43 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.404 -0.903 . . . . 0.0 111.106 -178.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 pt -65.46 138.17 23.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.822 0.344 . . . . 0.0 110.48 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.39 39.61 61.37 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.257 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' THR . . . . . 0.416 ' HA ' ' HD3' ' B' ' 16' ' ' PRO . 88.2 m -156.27 126.29 3.3 Favored Pre-proline 0 C--N 1.32 -0.707 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.22 111.76 2.35 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.555 2.17 . . . . 0.0 111.889 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.472 HG23 ' HB2' ' A' ' 9' ' ' TYR . 28.7 pt -87.18 138.87 18.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.834 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p -81.51 -173.74 4.56 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.87 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.41 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -67.49 139.68 49.9 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.41 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.7 mt-10 -82.56 58.32 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.231 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.472 ' HB2' HG23 ' B' ' 17' ' ' ILE . 34.3 t80 -158.58 160.68 36.87 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.287 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.3 t80 . . . . . 0 C--O 1.246 0.884 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.818 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . 0.429 HG13 ' HA2' ' A' ' 1' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.482 1.16 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.53 -164.58 38.08 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.654 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 14.7 tt -80.28 60.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.61 0 CA-C-O 122.235 1.017 . . . . 0.0 110.881 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.41 -115.19 0.6 Allowed Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' THR . . . . . 0.558 ' N ' ' HD3' ' B' ' 16' ' ' PRO . 4.5 m -148.91 56.48 2.49 Favored Pre-proline 0 C--N 1.318 -0.765 0 CA-C-O 121.013 0.435 . . . . 0.0 110.538 179.042 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . 0.558 ' HD3' ' N ' ' B' ' 15' ' ' THR . 5.7 Cg_exo -79.92 127.99 7.27 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.591 2.194 . . . . 0.0 111.819 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.4 pt -62.09 146.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.917 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -160.29 -174.34 4.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.406 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.429 ' HA2' HG13 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.447 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo -65.77 139.08 56.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.406 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 47.1 mt-10 -81.77 56.37 3.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.477 178.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -160.76 156.97 26.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.11 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.2 t80 . . . . . 0 C--O 1.246 0.883 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.689 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 42.9 t . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.65 -83.41 1.02 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -178.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.64 HD12 ' H ' ' B' ' 13' ' ' ILE . 0.2 OUTLIER -84.06 140.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 177.64 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.21 -46.84 14.46 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.173 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.11 137.44 53.15 Favored Pre-proline 0 C--N 1.315 -0.892 0 CA-C-N 115.362 -0.419 . . . . 0.0 111.127 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.13 101.24 0.69 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.633 2.222 . . . . 0.0 112.819 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.415 ' HB ' ' CD1' ' A' ' 9' ' ' TYR . 10.3 tt -73.16 147.03 10.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.614 179.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p -153.17 -170.65 3.68 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.554 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.475 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo -67.24 128.23 18.09 Favored 'Trans proline' 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.9 pt-20 -112.85 61.54 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.932 178.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.415 ' CD1' ' HB ' ' B' ' 17' ' ' ILE . 29.9 t80 -79.38 157.03 27.69 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.336 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.245 0.835 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.365 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.72 -147.95 9.8 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.523 -0.631 . . . . 0.0 111.523 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . 0.449 HD12 HG21 ' B' ' 13' ' ' ILE . 15.7 pt -76.64 127.34 37.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.921 0.391 . . . . 0.0 110.819 179.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.93 39.52 3.03 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.3 p -85.88 128.58 57.76 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.748 -0.226 . . . . 0.0 111.041 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -74.49 54.1 3.29 Favored 'Trans proline' 0 CA--C 1.531 0.358 0 C-N-CA 123.055 2.504 . . . . 0.0 112.598 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.499 HG23 ' N ' ' B' ' 18' ' ' SER . 38.8 mm -70.32 146.63 12.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.51 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' SER . . . . . 0.499 ' N ' HG23 ' B' ' 17' ' ' ILE . 1.9 p -145.55 -163.33 1.7 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.059 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.556 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.485 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.479 ' HD2' HG13 ' A' ' 6' ' ' VAL . 34.8 Cg_endo -65.53 138.95 56.72 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.556 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 4.2 mt-10 -84.02 55.3 3.24 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.243 0.544 . . . . 0.0 110.109 179.619 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -160.7 157.64 27.38 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.13 -179.596 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.6 t80 . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.381 -1.295 . . . . 0.0 108.498 179.635 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.481 1.091 0 CA-C-O 121.126 0.489 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.4 -62.86 3.73 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.098 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 49.4 mm -79.01 120.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.57 -62.55 2.32 Favored Glycine 0 C--O 1.229 -0.19 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.793 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 6.3 p -99.15 120.65 57.74 Favored Pre-proline 0 C--N 1.316 -0.881 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.7 -49.52 5.37 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.443 2.095 . . . . 0.0 112.412 -179.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.62 HD12 ' HB2' ' A' ' 7' ' ' PRO . 12.8 tt -66.76 142.9 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.532 0.682 . . . . 0.0 111.679 -179.82 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p -98.94 -171.69 2.14 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' TYR . . . . . 0.413 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.62 ' HB2' HD12 ' B' ' 17' ' ' ILE . 22.9 Cg_endo -62.94 141.42 84.12 Favored 'Trans proline' 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . 0.413 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 41.7 mt-10 -79.57 62.11 3.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.453 0.644 . . . . 0.0 110.684 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.414 ' CD2' ' HG2' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -78.36 151.97 32.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.009 -179.929 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.0 t80 . . . . . 0 C--O 1.248 0.979 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.452 -0.356 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.4 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.4 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 C--O 1.233 0.225 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.437 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.437 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 120.752 0.311 . . . . 0.0 110.715 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.44 0 CA-C-O 120.692 0.282 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' TYR . . . . . 0.496 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo . . . . . 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.434 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.434 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo . . . . . 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.924 0.392 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.413 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.414 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo . . . . . 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.81 0.338 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.0 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.416 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.416 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 110.72 -0.104 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' TYR . . . . . 0.484 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.484 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.451 -0.388 0 CA-C-O 120.593 0.235 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' TYR . . . . . 0.507 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.507 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo . . . . . 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.453 -0.312 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo . . . . . 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 110.394 -0.225 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' TYR . . . . . 0.481 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 25.2 Cg_exo . . . . . 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' SER . . . . . 0.426 ' HB2' ' H ' ' B' ' 19' ' ' PHE . 1.4 p . . . . . 0 N--CA 1.453 -0.293 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.426 ' H ' ' HB2' ' B' ' 18' ' ' SER . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.442 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.442 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo . . . . . 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 110.517 -0.179 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.414 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.414 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo . . . . . 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.684 0.278 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo . . . . . 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 110.646 -0.131 . . . . 0.0 110.646 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.234 0.271 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo . . . . . 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.451 -0.411 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' TYR . . . . . 0.493 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 21' ' ' GLY . . . . . 0.426 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' HIS . . . . . 0.426 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.532 0.205 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo . . . . . 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.619 ' N ' ' HG1' ' B' ' 15' ' ' THR . 4.0 t . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.297 0.57 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' GLY . . . . . 0.716 ' HA2' HD11 ' B' ' 17' ' ' ILE . . . 72.62 -70.33 1.14 Allowed Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.398 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 12.1 tt -71.7 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 33.75 85.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.079 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.619 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 11.7 m -127.79 130.77 23.61 Favored Pre-proline 0 C--N 1.319 -0.74 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.13 60.46 3.14 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 123.129 2.552 . . . . 0.0 112.983 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.716 HD11 ' HA2' ' B' ' 12' ' ' GLY . 33.9 mt -60.51 141.37 17.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.155 0.502 . . . . 0.0 110.179 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p -160.4 -159.85 0.73 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.964 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.4 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.4 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -70.52 121.04 7.59 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -92.72 62.58 3.8 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.077 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -79.81 143.38 34.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.251 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.197 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.75 -60.94 3.71 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 -178.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.9 tt -95.68 125.6 48.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.2 -65.45 3.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.209 -0.519 . . . . 0.0 112.552 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.0 p -98.33 133.97 22.37 Favored Pre-proline 0 C--N 1.317 -0.842 0 CA-C-O 120.675 0.274 . . . . 0.0 110.611 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.482 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 68.8 Cg_endo -74.63 -131.88 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.889 2.393 . . . . 0.0 113.135 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.482 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 11.8 tt -165.24 153.73 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.813 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p -158.39 -170.5 3.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.508 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.437 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.437 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.45 123.82 10.94 Favored 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.449 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.6 pt-20 -104.75 58.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.99 178.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.424 ' HB3' HG13 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -80.82 146.88 30.7 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.517 -179.823 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 26.0 t80 . . . . . 0 C--O 1.247 0.925 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.687 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.476 0.845 0 CA-C-O 120.923 0.392 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.45 140.42 5.01 Favored Glycine 0 N--CA 1.445 -0.765 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 61.4 mt -64.91 111.15 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.05 -39.52 1.06 Allowed Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.674 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 1.9 m -77.4 124.9 86.87 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.608 -0.296 . . . . 0.0 110.667 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.29 118.0 5.34 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.614 2.209 . . . . 0.0 111.837 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.5 pt -77.11 148.5 6.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.675 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -155.14 177.83 10.89 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.426 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -65.52 133.87 36.21 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.426 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.1 pt-20 -108.46 55.68 0.64 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.245 0.545 . . . . 0.0 110.599 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 30.4 t80 -160.81 156.64 25.48 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.014 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.6 t80 . . . . . 0 C--O 1.25 1.1 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.688 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.599 ' N ' ' HH ' ' A' ' 9' ' ' TYR . 22.7 m . . . . . 0 N--CA 1.479 1.014 0 CA-C-O 120.724 0.297 . . . . 0.0 110.57 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.4 -111.79 4.04 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.458 -0.877 . . . . 0.0 111.907 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 10.9 tt -62.19 131.63 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.618 0.247 . . . . 0.0 110.619 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.8 -48.38 85.52 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.952 -179.05 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.414 ' O ' HG13 ' B' ' 17' ' ' ILE . 17.2 m 71.05 132.94 0.04 OUTLIER Pre-proline 0 CA--C 1.538 0.494 0 O-C-N 123.897 0.41 . . . . 0.0 111.49 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 8.2 Cg_exo -72.58 56.04 2.74 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.227 2.618 . . . . 0.0 112.32 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.563 HG12 ' CB ' ' A' ' 9' ' ' TYR . 2.1 pp -78.95 157.77 4.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.054 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p -88.59 -166.81 1.69 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.731 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.72 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo -65.37 139.23 58.67 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.72 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 26.8 mt-10 -83.75 56.08 3.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.189 0.518 . . . . 0.0 110.067 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.599 ' HH ' ' N ' ' B' ' 11' ' ' VAL . 64.9 t80 -160.71 155.08 23.34 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.509 -0.768 . . . . 0.0 110.939 -178.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 . . . . . 0 C--O 1.247 0.946 0 CA-C-N 114.955 -1.02 . . . . 0.0 108.562 178.935 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.479 1.0 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 12' ' ' GLY . . . . . 0.436 ' HA3' ' HE1' ' A' ' 10' ' ' PHE . . . -73.84 142.68 31.23 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.683 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.421 ' H ' HG13 ' B' ' 13' ' ' ILE . 2.4 pp -74.42 141.4 16.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.719 0.295 . . . . 0.0 110.292 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 -44.16 3.12 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.178 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 19.9 m -147.2 120.33 4.88 Favored Pre-proline 0 C--N 1.317 -0.836 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -56.66 -47.05 25.52 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 123.207 2.605 . . . . 0.0 113.841 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.622 HD13 ' H ' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -123.32 147.84 27.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.006 0.431 . . . . 0.0 111.096 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -136.96 -175.33 4.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.742 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.434 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.434 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo -64.82 137.82 55.27 Favored 'Trans proline' 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.466 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 3.6 pt-20 -130.36 75.87 1.68 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.188 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.565 ' CD1' HG22 ' B' ' 17' ' ' ILE . 40.4 t80 -79.13 147.91 32.55 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.62 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' HE1' ' HA3' ' B' ' 12' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.311 -1.089 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.9 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.505 ' HA ' ' OH ' ' A' ' 9' ' ' TYR . 10.6 p . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.83 -144.38 4.19 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.155 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 20.2 pt -77.26 49.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.115 0.483 . . . . 0.0 111.799 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.61 120.09 0.5 Allowed Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.0 p -131.82 65.11 74.91 Favored Pre-proline 0 C--N 1.319 -0.72 0 N-CA-C 111.436 0.162 . . . . 0.0 111.436 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.8 -38.93 12.47 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.522 2.148 . . . . 0.0 111.869 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 37.8 mm 71.36 142.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.379 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p -161.9 169.24 21.56 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.311 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.452 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.413 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.414 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo -65.14 135.81 45.18 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.452 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.3 pt-20 -115.67 56.78 0.75 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.998 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.505 ' OH ' ' HA ' ' B' ' 11' ' ' VAL . 51.3 t80 -160.7 154.3 22.25 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.149 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.3 p90 . . . . . 0 C--O 1.253 1.285 0 CA-C-O 117.655 -1.164 . . . . 0.0 108.844 179.546 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.476 0.861 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.69 -113.17 0.28 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 19.6 mt -75.4 65.09 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.153 0.502 . . . . 0.0 110.371 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.92 -40.88 2.33 Favored Glycine 0 C--N 1.33 0.203 0 CA-C-N 116.009 -0.542 . . . . 0.0 112.971 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.707 ' HB ' HG12 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -67.01 135.5 94.05 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-O 121.158 0.504 . . . . 0.0 112.097 -179.678 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.55 -25.0 41.38 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 123.238 2.625 . . . . 0.0 112.314 -179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.707 HG12 ' HB ' ' B' ' 15' ' ' THR . 28.8 pt -58.84 158.16 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.826 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.65 168.74 18.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.386 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.431 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.0 Cg_exo -67.77 140.22 50.4 Favored 'Trans proline' 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.431 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 49.9 mt-10 -83.49 53.11 2.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.346 0.593 . . . . 0.0 110.071 178.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -160.83 154.79 22.66 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.942 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 . . . . . 0 C--O 1.245 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.063 179.639 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' B' ' 16' ' ' PRO . 12.3 p . . . . . 0 N--CA 1.479 0.977 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' GLY . . . . . 0.403 ' H ' ' HA ' ' B' ' 16' ' ' PRO . . . 71.65 -120.39 8.15 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.678 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.6 tp -61.62 144.32 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.083 0.468 . . . . 0.0 111.4 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.74 -57.73 5.04 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.398 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.1 m -157.5 113.53 1.87 Allowed Pre-proline 0 C--N 1.315 -0.895 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.468 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 26.6 Cg_exo -63.34 -55.49 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.882 2.388 . . . . 0.0 112.315 -179.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 6.1 tt -71.9 137.87 22.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.337 0.589 . . . . 0.0 110.846 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p -161.79 -167.6 1.73 Allowed 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.339 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.436 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.416 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.416 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo -65.93 137.6 49.53 Favored 'Trans proline' 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 46.1 mt-10 -80.43 58.01 3.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.449 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -79.99 154.66 28.08 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.526 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.251 1.18 0 CA-C-O 117.547 -1.216 . . . . 0.0 109.382 179.605 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.652 ' N ' ' HG ' ' B' ' 18' ' ' SER . 35.9 m . . . . . 0 N--CA 1.481 1.108 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.23 -145.17 37.28 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.646 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 18.4 pt -83.35 52.78 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.923 0.392 . . . . 0.0 111.919 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.29 -128.79 0.97 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.743 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 21.2 p -82.4 133.7 49.71 Favored Pre-proline 0 C--N 1.315 -0.922 0 CA-C-O 120.573 0.225 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.66 -53.07 3.64 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.477 2.118 . . . . 0.0 110.82 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 20.5 mt -75.42 141.48 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' SER . . . . . 0.652 ' HG ' ' N ' ' B' ' 11' ' ' VAL . 0.6 OUTLIER -161.51 -163.28 0.97 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.72 -179.401 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.569 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.587 ' HA2' HG22 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.484 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo -66.74 140.3 55.57 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.569 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 49.2 mt-10 -83.58 55.82 3.36 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.089 178.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -160.95 157.81 27.04 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.967 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.1 t80 . . . . . 0 C--O 1.251 1.166 0 CA-C-O 117.403 -1.284 . . . . 0.0 108.542 179.591 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' B' ' 16' ' ' PRO . 18.9 m . . . . . 0 N--CA 1.477 0.911 0 CA-C-O 120.645 0.259 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.4 -132.54 12.71 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.849 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 16.1 tt -66.5 149.1 11.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.048 0.451 . . . . 0.0 111.601 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.21 -54.42 4.87 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.993 -0.548 . . . . 0.0 112.442 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 83.2 m -157.98 119.99 2.02 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.477 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 34.8 Cg_endo -66.15 -36.03 30.66 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.731 2.288 . . . . 0.0 112.291 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.424 ' H ' HG13 ' B' ' 17' ' ' ILE . 6.1 mt -64.92 161.61 2.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.059 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p -79.34 -165.8 0.84 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.127 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.727 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.507 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -62.76 142.4 88.89 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.727 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 43.4 mt-10 -80.11 56.38 2.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.313 0.578 . . . . 0.0 110.901 179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -79.14 151.87 31.07 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.824 . . . . 0.0 111.289 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.9 t80 . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.388 -1.292 . . . . 0.0 108.576 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.694 ' N ' ' HG1' ' B' ' 15' ' ' THR . 20.6 m . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.31 -71.87 1.47 Allowed Glycine 0 N--CA 1.453 -0.218 0 N-CA-C 111.827 -0.509 . . . . 0.0 111.827 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.68 117.83 23.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 62.35 21.36 62.07 Favored Glycine 0 C--O 1.226 -0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 113.451 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.694 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 0.2 OUTLIER -161.1 122.24 1.65 Allowed Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.605 0.203 . . . . 0.0 110.56 179.561 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 39.3 Cg_exo -60.85 -44.19 26.88 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.64 2.227 . . . . 0.0 111.935 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 41.0 pt -67.08 139.18 21.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.774 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 18' ' ' SER . . . . . 0.5 ' HA ' ' HB ' ' B' ' 11' ' ' VAL . 3.0 p -158.49 -167.81 2.26 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.179 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.445 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -68.16 138.33 43.14 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.9 mt-10 -81.47 58.22 3.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.051 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -79.68 154.55 28.54 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.623 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.252 1.184 0 CA-C-O 117.485 -1.245 . . . . 0.0 109.377 179.676 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.85 -134.89 3.19 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.526 -0.63 . . . . 0.0 111.526 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.908 ' H ' HD13 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -77.3 58.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.346 0.593 . . . . 0.0 111.014 179.345 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.0 -25.18 27.98 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.045 -179.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.452 ' HB ' ' HE1' ' B' ' 19' ' ' PHE . 8.3 p -66.54 122.22 80.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 120.998 0.428 . . . . 0.0 111.572 -179.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 16.6 Cg_exo -67.98 -52.36 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.89 2.393 . . . . 0.0 111.998 -179.567 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.658 ' HB ' ' CE1' ' A' ' 9' ' ' TYR . 39.9 pt -74.24 162.28 4.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.659 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.53 157.46 18.61 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.452 ' HE1' ' HB ' ' B' ' 15' ' ' THR . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.457 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo -62.84 141.5 84.95 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.457 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 50.8 mt-10 -80.0 54.88 1.99 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.077 0.465 . . . . 0.0 110.742 179.371 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.658 ' CE1' ' HB ' ' B' ' 17' ' ' ILE . 62.6 m-85 -143.25 155.18 44.43 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.984 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.5 p90 . . . . . 0 C--O 1.252 1.193 0 CA-C-O 117.447 -1.263 . . . . 0.0 109.207 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.704 ' N ' ' HG1' ' B' ' 15' ' ' THR . 57.3 t . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.37 -85.71 0.25 Allowed Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 51.3 mm -72.85 125.81 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 178.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.64 39.85 90.49 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.26 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.704 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 55.5 m -154.18 120.42 2.79 Favored Pre-proline 0 C--N 1.319 -0.752 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.483 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 85.4 Cg_endo -83.16 -138.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.753 2.302 . . . . 0.0 112.302 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.483 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 32.3 pt -58.95 135.61 23.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.046 0.45 . . . . 0.0 110.48 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p -160.24 -159.95 0.75 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.394 -178.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.571 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 25.2 Cg_exo -62.67 140.11 79.03 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.571 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 7.3 mt-10 -80.79 56.92 2.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.305 0.574 . . . . 0.0 110.812 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -79.58 150.93 30.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.029 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 18.3 t80 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.983 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.25 -61.95 4.1 Favored Glycine 0 C--O 1.227 -0.295 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 41.4 mm -82.09 155.39 4.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.44 -36.55 53.81 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.987 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 2.4 p -73.41 144.96 84.64 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-O 120.95 0.405 . . . . 0.0 110.922 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.85 44.27 0.5 Allowed 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 123.176 2.584 . . . . 0.0 113.282 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.49 HG21 ' CD1' ' A' ' 9' ' ' TYR . 40.5 pt -61.16 143.38 14.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 CA-C-O 120.98 0.419 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 18' ' ' SER . . . . . 0.426 ' HB2' ' H ' ' B' ' 19' ' ' PHE . 1.4 p -159.05 -153.68 0.38 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.571 -0.741 . . . . 0.0 109.89 -178.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.426 ' H ' ' HB2' ' B' ' 18' ' ' SER . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.442 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.442 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo -70.09 128.45 15.74 Favored 'Trans proline' 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -105.8 75.73 1.14 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.447 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' HG21 ' B' ' 17' ' ' ILE . 68.4 t80 -77.21 154.58 32.93 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.951 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.7 t80 . . . . . 0 C--O 1.245 0.825 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.412 179.905 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.764 ' N ' ' HG1' ' B' ' 15' ' ' THR . 31.3 t . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 71.99 -118.7 7.05 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.696 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.678 ' H ' HD13 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -62.92 136.32 26.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.974 0.416 . . . . 0.0 110.668 179.333 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 35.73 82.55 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.299 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.764 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 73.4 m -156.55 126.81 3.37 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -82.34 -148.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.479 2.119 . . . . 0.0 111.793 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 tt -66.33 139.92 20.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.245 0.545 . . . . 0.0 110.494 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -157.74 -168.54 2.57 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.517 -179.465 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.438 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.414 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.414 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -67.02 139.72 52.05 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.0 mt-10 -81.15 55.3 2.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.251 0.548 . . . . 0.0 110.489 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -160.92 156.5 25.01 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.994 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--O 1.246 0.909 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.665 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.783 ' N ' ' HG1' ' B' ' 15' ' ' THR . 45.7 t . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.12 -119.59 7.43 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.404 -0.903 . . . . 0.0 111.106 -178.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 pt -65.46 138.17 23.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.822 0.344 . . . . 0.0 110.48 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.39 39.61 61.37 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.257 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.783 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 88.2 m -156.27 126.29 3.3 Favored Pre-proline 0 C--N 1.32 -0.707 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.22 111.76 2.35 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.555 2.17 . . . . 0.0 111.889 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.7 pt -87.18 138.87 18.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.834 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p -81.51 -173.74 4.56 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.87 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.449 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo -67.49 139.68 49.9 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.449 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.7 mt-10 -82.56 58.32 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.231 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 t80 -158.58 160.68 36.87 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.287 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.3 t80 . . . . . 0 C--O 1.246 0.884 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.818 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.68 HG13 ' HA2' ' A' ' 1' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.482 1.16 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.53 -164.58 38.08 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.654 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 14.7 tt -80.28 60.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.61 0 CA-C-O 122.235 1.017 . . . . 0.0 110.881 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.41 -115.19 0.6 Allowed Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.559 ' N ' ' HD3' ' B' ' 16' ' ' PRO . 4.5 m -148.91 56.48 2.49 Favored Pre-proline 0 C--N 1.318 -0.765 0 CA-C-O 121.013 0.435 . . . . 0.0 110.538 179.042 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' B' ' 15' ' ' THR . 5.7 Cg_exo -79.92 127.99 7.27 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.591 2.194 . . . . 0.0 111.819 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.4 pt -62.09 146.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.917 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' SER . . . . . 0.673 ' HG ' ' N ' ' B' ' 11' ' ' VAL . 0.7 OUTLIER -160.29 -174.34 4.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.689 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.445 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.68 ' HA2' HG13 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo -65.77 139.08 56.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 47.1 mt-10 -81.77 56.37 3.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.477 178.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -160.76 156.97 26.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.11 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.2 t80 . . . . . 0 C--O 1.246 0.883 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.689 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 42.9 t . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.65 -83.41 1.02 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -178.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' ILE . . . . . 0.804 ' H ' HD13 ' B' ' 13' ' ' ILE . 0.2 OUTLIER -84.06 140.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 177.64 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.21 -46.84 14.46 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.173 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.11 137.44 53.15 Favored Pre-proline 0 C--N 1.315 -0.892 0 CA-C-N 115.362 -0.419 . . . . 0.0 111.127 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.13 101.24 0.69 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.633 2.222 . . . . 0.0 112.819 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.428 ' HB ' ' CD1' ' A' ' 9' ' ' TYR . 10.3 tt -73.16 147.03 10.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.614 179.387 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p -153.17 -170.65 3.68 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.554 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.475 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo -67.24 128.23 18.09 Favored 'Trans proline' 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.9 pt-20 -112.85 61.54 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.932 178.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.428 ' CD1' ' HB ' ' B' ' 17' ' ' ILE . 29.9 t80 -79.38 157.03 27.69 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.336 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.245 0.835 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.365 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.72 -147.95 9.8 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.523 -0.631 . . . . 0.0 111.523 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 15.7 pt -76.64 127.34 37.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.921 0.391 . . . . 0.0 110.819 179.367 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.93 39.52 3.03 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.3 p -85.88 128.58 57.76 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.748 -0.226 . . . . 0.0 111.041 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -74.49 54.1 3.29 Favored 'Trans proline' 0 CA--C 1.531 0.358 0 C-N-CA 123.055 2.504 . . . . 0.0 112.598 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.4 HD12 ' HB2' ' A' ' 9' ' ' TYR . 38.8 mm -70.32 146.63 12.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.51 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p -145.55 -163.33 1.7 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.059 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.552 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 21' ' ' GLY . . . . . 0.426 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . 0.426 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.53 138.95 56.72 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.552 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 4.2 mt-10 -84.02 55.3 3.24 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.243 0.544 . . . . 0.0 110.109 179.619 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.4 ' HB2' HD12 ' B' ' 17' ' ' ILE . 45.9 t80 -160.7 157.64 27.38 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.13 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.6 t80 . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.381 -1.295 . . . . 0.0 108.498 179.635 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 11' ' ' VAL . . . . . 0.661 ' N ' ' HG1' ' B' ' 15' ' ' THR . 7.4 m . . . . . 0 N--CA 1.481 1.091 0 CA-C-O 121.126 0.489 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.4 -62.86 3.73 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.098 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 49.4 mm -79.01 120.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.57 -62.55 2.32 Favored Glycine 0 C--O 1.229 -0.19 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.793 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' THR . . . . . 0.661 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 6.3 p -99.15 120.65 57.74 Favored Pre-proline 0 C--N 1.316 -0.881 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.7 -49.52 5.37 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.443 2.095 . . . . 0.0 112.412 -179.394 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 12.8 tt -66.76 142.9 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.532 0.682 . . . . 0.0 111.679 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p -98.94 -171.69 2.14 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' TYR . . . . . 0.452 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.419 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . 22.9 Cg_endo -62.94 141.42 84.12 Favored 'Trans proline' 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . 0.452 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 41.7 mt-10 -79.57 62.11 3.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.453 0.644 . . . . 0.0 110.684 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.419 ' CD2' ' HG2' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -78.36 151.97 32.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.009 -179.929 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.0 t80 . . . . . 0 C--O 1.248 0.979 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.452 -0.356 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.4 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.4 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo . . . . . 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p . . . . . 0 C--O 1.233 0.225 0 N-CA-C 110.508 -0.182 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.437 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.437 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo . . . . . 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.451 -0.396 0 CA-C-O 120.752 0.311 . . . . 0.0 110.715 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo . . . . . 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p . . . . . 0 N--CA 1.45 -0.44 0 CA-C-O 120.692 0.282 . . . . 0.0 110.731 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . 0.496 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo . . . . . 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.45 -0.442 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.434 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.434 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo . . . . . 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.452 -0.342 0 CA-C-O 120.924 0.392 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.413 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.414 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo . . . . . 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.452 -0.359 0 CA-C-O 120.81 0.338 . . . . 0.0 111.386 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.0 Cg_exo . . . . . 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.453 -0.325 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.416 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.416 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo . . . . . 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 110.72 -0.104 . . . . 0.0 110.72 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . 0.484 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.484 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo . . . . . 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.451 -0.388 0 CA-C-O 120.593 0.235 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . 0.507 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.507 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo . . . . . 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.451 -0.422 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo . . . . . 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.453 -0.312 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo . . . . . 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p . . . . . 0 N--CA 1.45 -0.434 0 N-CA-C 110.394 -0.225 . . . . 0.0 110.394 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . 0.481 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 25.2 Cg_exo . . . . . 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . 0.426 ' HB2' ' H ' ' B' ' 19' ' ' PHE . 1.4 p . . . . . 0 N--CA 1.453 -0.293 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.426 ' H ' ' HB2' ' B' ' 18' ' ' SER . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.442 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.442 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo . . . . . 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p . . . . . 0 N--CA 1.452 -0.343 0 N-CA-C 110.517 -0.179 . . . . 0.0 110.517 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.414 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.414 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo . . . . . 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.452 -0.37 0 CA-C-O 120.684 0.278 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo . . . . . 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.453 -0.298 0 N-CA-C 110.646 -0.131 . . . . 0.0 110.646 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo . . . . . 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.234 0.271 0 N-CA-C 110.554 -0.165 . . . . 0.0 110.554 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo . . . . . 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.451 -0.411 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . 0.493 ' CE1' ' HB ' ' A' ' 6' ' ' VAL . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . 0.426 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . 0.426 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo . . . . . 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.453 -0.289 0 CA-C-O 120.532 0.205 . . . . 0.0 111.111 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_endo . . . . . 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.619 ' N ' ' HG1' ' B' ' 15' ' ' THR . 4.0 t . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.297 0.57 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . 0.716 ' HA2' HD11 ' B' ' 17' ' ' ILE . . . 72.62 -70.33 1.14 Allowed Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.698 -0.683 . . . . 0.0 112.398 -179.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 12.1 tt -71.7 132.77 32.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 33.75 85.58 Favored Glycine 0 C--O 1.228 -0.275 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.079 -179.251 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.619 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 11.7 m -127.79 130.77 23.61 Favored Pre-proline 0 C--N 1.319 -0.74 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.13 60.46 3.14 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 123.129 2.552 . . . . 0.0 112.983 -179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.716 HD11 ' HA2' ' B' ' 12' ' ' GLY . 33.9 mt -60.51 141.37 17.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.155 0.502 . . . . 0.0 110.179 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.1 p -160.4 -159.85 0.73 Allowed 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.964 -179.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -130.93 168.04 17.98 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.944 0.402 . . . . 0.0 111.257 -179.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 39.0 p90 -154.35 163.59 39.92 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.792 178.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.4 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.664 -1.076 . . . . 0.0 112.347 -179.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.611 0 N-CA-C 111.689 -0.565 . . . . 0.0 111.689 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -179.89 -127.25 1.1 Allowed Glycine 0 N--CA 1.448 -0.54 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.73 133.76 35.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.89 -140.54 3.63 Favored Glycine 0 N--CA 1.449 -0.448 0 C-N-CA 120.364 -0.922 . . . . 0.0 112.4 -179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.4 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 65.5 m80 -128.44 -44.74 1.37 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.601 0.239 . . . . 0.0 111.277 -179.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 22.8 t -87.21 125.94 64.31 Favored Pre-proline 0 C--N 1.326 -0.452 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_exo -70.52 121.04 7.59 Favored 'Trans proline' 0 N--CA 1.463 -0.268 0 C-N-CA 122.583 2.189 . . . . 0.0 112.927 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -92.72 62.58 3.8 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.077 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -79.81 143.38 34.45 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.251 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 . . . . . 0 C--O 1.247 0.922 0 CA-C-N 115.652 -0.704 . . . . 0.0 109.197 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 N--CA 1.479 1.012 0 N-CA-C 109.953 -0.388 . . . . 0.0 109.953 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 77.75 -60.94 3.71 Favored Glycine 0 N--CA 1.451 -0.305 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 -178.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.9 tt -95.68 125.6 48.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 178.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 77.2 -65.45 3.02 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 121.209 -0.519 . . . . 0.0 112.552 -179.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.0 p -98.33 133.97 22.37 Favored Pre-proline 0 C--N 1.317 -0.842 0 CA-C-O 120.675 0.274 . . . . 0.0 110.611 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.482 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 68.8 Cg_endo -74.63 -131.88 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.507 0 C-N-CA 122.889 2.393 . . . . 0.0 113.135 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.482 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 11.8 tt -165.24 153.73 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.813 -179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.5 p -158.39 -170.5 3.12 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.508 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -138.16 172.76 12.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.922 0.391 . . . . 0.0 110.953 -179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.0 p90 -155.43 163.46 40.03 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.906 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.437 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.719 0 CA-C-O 118.925 -0.931 . . . . 0.0 112.235 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.654 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.19 -128.37 1.12 Allowed Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.73 134.12 36.39 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.98 -140.51 3.63 Favored Glycine 0 N--CA 1.448 -0.546 0 C-N-CA 120.37 -0.919 . . . . 0.0 112.373 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.437 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.8 m80 -128.98 -44.32 1.3 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.673 0.237 . . . . 0.0 111.237 -179.632 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.04 124.55 72.18 Favored Pre-proline 0 C--N 1.327 -0.409 0 N-CA-C 110.007 -0.368 . . . . 0.0 110.007 179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -68.45 123.82 10.94 Favored 'Trans proline' 0 CA--C 1.528 0.22 0 C-N-CA 122.438 2.092 . . . . 0.0 113.229 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.449 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.6 pt-20 -104.75 58.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.99 178.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.424 ' HB3' HG13 ' B' ' 17' ' ' ILE . 0.2 OUTLIER -80.82 146.88 30.7 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.517 -179.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 26.0 t80 . . . . . 0 C--O 1.247 0.925 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.687 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 N--CA 1.476 0.845 0 CA-C-O 120.923 0.392 . . . . 0.0 110.431 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -176.45 140.42 5.01 Favored Glycine 0 N--CA 1.445 -0.765 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 61.4 mt -64.91 111.15 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.05 -39.52 1.06 Allowed Glycine 0 N--CA 1.445 -0.719 0 C-N-CA 120.899 -0.667 . . . . 0.0 111.674 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 1.9 m -77.4 124.9 86.87 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 115.608 -0.296 . . . . 0.0 110.667 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_exo -68.29 118.0 5.34 Favored 'Trans proline' 0 N--CA 1.463 -0.291 0 C-N-CA 122.614 2.209 . . . . 0.0 111.837 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.5 pt -77.11 148.5 6.68 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.675 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -155.14 177.83 10.89 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.715 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 41.9 m-85 -137.15 175.08 9.93 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.684 -179.006 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.426 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 34.7 p90 -153.27 161.08 42.77 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.724 178.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.89 0 CA-C-O 118.492 -1.171 . . . . 0.0 112.527 -179.966 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.545 0 N-CA-C 112.267 -0.333 . . . . 0.0 112.267 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.25 -128.76 1.15 Allowed Glycine 0 CA--C 1.505 -0.534 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.722 -179.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.95 133.62 33.9 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.68 -142.98 5.06 Favored Glycine 0 N--CA 1.448 -0.561 0 C-N-CA 120.6 -0.81 . . . . 0.0 111.956 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -131.22 -42.41 1.08 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.814 0.307 . . . . 0.0 111.057 -179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.9 t -87.75 125.84 63.57 Favored Pre-proline 0 C--N 1.326 -0.428 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_endo -65.52 133.87 36.21 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.618 2.212 . . . . 0.0 112.824 -179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.426 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.1 pt-20 -108.46 55.68 0.64 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.245 0.545 . . . . 0.0 110.599 179.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 30.4 t80 -160.81 156.64 25.48 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.014 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.6 t80 . . . . . 0 C--O 1.25 1.1 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.688 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.599 ' N ' ' HH ' ' A' ' 9' ' ' TYR . 22.7 m . . . . . 0 N--CA 1.479 1.014 0 CA-C-O 120.724 0.297 . . . . 0.0 110.57 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 91.4 -111.79 4.04 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.458 -0.877 . . . . 0.0 111.907 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 10.9 tt -62.19 131.63 27.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.618 0.247 . . . . 0.0 110.619 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -58.8 -48.38 85.52 Favored Glycine 0 C--N 1.332 0.361 0 C-N-CA 121.223 -0.513 . . . . 0.0 112.952 -179.05 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.414 ' O ' HG13 ' B' ' 17' ' ' ILE . 17.2 m 71.05 132.94 0.04 OUTLIER Pre-proline 0 CA--C 1.538 0.494 0 O-C-N 123.897 0.41 . . . . 0.0 111.49 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 8.2 Cg_exo -72.58 56.04 2.74 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 123.227 2.618 . . . . 0.0 112.32 -179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.563 HG12 ' CB ' ' A' ' 9' ' ' TYR . 2.1 pp -78.95 157.77 4.77 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.054 -179.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.5 p -88.59 -166.81 1.69 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.731 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -134.3 179.49 6.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.085 0.469 . . . . 0.0 111.164 -178.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.72 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.0 OUTLIER -159.39 163.07 35.83 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.706 178.493 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.687 -1.063 . . . . 0.0 112.262 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.453 0 N-CA-C 111.941 -0.464 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -169.99 -130.19 1.18 Allowed Glycine 0 CA--C 1.504 -0.597 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.41 133.02 36.56 Favored 'General case' 0 C--N 1.314 -0.949 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -142.63 4.97 Favored Glycine 0 N--CA 1.447 -0.575 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.162 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.5 m80 -133.16 -44.54 0.85 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.707 0.253 . . . . 0.0 111.129 -179.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 25.7 t -87.8 125.47 64.71 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.3 Cg_exo -65.37 139.23 58.67 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 123.009 2.473 . . . . 0.0 112.831 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.72 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 26.8 mt-10 -83.75 56.08 3.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.189 0.518 . . . . 0.0 110.067 179.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.599 ' HH ' ' N ' ' B' ' 11' ' ' VAL . 64.9 t80 -160.71 155.08 23.34 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.509 -0.768 . . . . 0.0 110.939 -178.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.2 m-85 . . . . . 0 C--O 1.247 0.946 0 CA-C-N 114.955 -1.02 . . . . 0.0 108.562 178.935 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.479 1.0 0 N-CA-C 109.878 -0.415 . . . . 0.0 109.878 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . 0.436 ' HA3' ' HE1' ' A' ' 10' ' ' PHE . . . -73.84 142.68 31.23 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.958 -0.639 . . . . 0.0 112.683 -179.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.421 ' H ' HG13 ' B' ' 13' ' ' ILE . 2.4 pp -74.42 141.4 16.11 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.719 0.295 . . . . 0.0 110.292 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 -44.16 3.12 Favored Glycine 0 N--CA 1.453 -0.203 0 C-N-CA 120.843 -0.694 . . . . 0.0 112.178 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 19.9 m -147.2 120.33 4.88 Favored Pre-proline 0 C--N 1.317 -0.836 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -56.66 -47.05 25.52 Favored 'Trans proline' 0 C--N 1.344 0.302 0 C-N-CA 123.207 2.605 . . . . 0.0 113.841 -178.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.622 HD13 ' H ' ' B' ' 17' ' ' ILE . 0.2 OUTLIER -123.32 147.84 27.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-O 121.006 0.431 . . . . 0.0 111.096 -179.502 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -136.96 -175.33 4.0 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.742 179.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -139.64 171.71 13.84 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.047 0.451 . . . . 0.0 110.984 -179.121 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.466 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 43.7 p90 -153.04 163.07 40.52 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.419 -0.81 . . . . 0.0 109.85 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.434 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.955 -0.914 . . . . 0.0 112.24 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.626 0 N-CA-C 111.578 -0.609 . . . . 0.0 111.578 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.51 -128.09 1.08 Allowed Glycine 0 CA--C 1.505 -0.565 0 N-CA-C 111.435 -0.666 . . . . 0.0 111.435 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.62 133.15 36.26 Favored 'General case' 0 C--N 1.313 -1.017 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -176.9 -139.9 3.41 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.389 -179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.434 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.0 m80 -130.77 -44.59 1.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.636 0.218 . . . . 0.0 111.191 -179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.439 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.5 t -84.47 126.33 69.4 Favored Pre-proline 0 C--N 1.326 -0.418 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 23.0 Cg_exo -64.82 137.82 55.27 Favored 'Trans proline' 0 CA--C 1.528 0.202 0 C-N-CA 122.829 2.353 . . . . 0.0 113.18 -179.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.466 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 3.6 pt-20 -130.36 75.87 1.68 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.188 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.565 ' CD1' HG22 ' B' ' 17' ' ' ILE . 40.4 t80 -79.13 147.91 32.55 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.62 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' HE1' ' HA3' ' B' ' 12' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.311 -1.089 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.9 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.505 ' HA ' ' OH ' ' A' ' 9' ' ' TYR . 10.6 p . . . . . 0 N--CA 1.475 0.816 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.83 -144.38 4.19 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.618 -0.801 . . . . 0.0 112.155 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 20.2 pt -77.26 49.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-O 121.115 0.483 . . . . 0.0 111.799 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 166.61 120.09 0.5 Allowed Glycine 0 N--CA 1.444 -0.833 0 N-CA-C 111.545 -0.622 . . . . 0.0 111.545 179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.0 p -131.82 65.11 74.91 Favored Pre-proline 0 C--N 1.319 -0.72 0 N-CA-C 111.436 0.162 . . . . 0.0 111.436 -179.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -67.8 -38.93 12.47 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.522 2.148 . . . . 0.0 111.869 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 37.8 mm 71.36 142.2 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.379 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.6 p -161.9 169.24 21.56 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.311 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 m-85 -138.74 174.19 10.79 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.726 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.452 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 38.4 p90 -153.15 162.76 40.94 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.64 178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.413 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.74 0 CA-C-O 118.919 -0.934 . . . . 0.0 112.235 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 112.112 -0.395 . . . . 0.0 112.112 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.64 -128.73 1.12 Allowed Glycine 0 CA--C 1.506 -0.521 0 C-N-CA 120.741 -0.742 . . . . 0.0 111.799 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.31 133.96 33.63 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.02 -140.92 4.19 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.484 -0.865 . . . . 0.0 112.167 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.413 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -132.58 -44.91 0.89 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.611 0.243 . . . . 0.0 111.127 -179.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.414 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.9 t -86.39 126.75 63.55 Favored Pre-proline 0 C--N 1.326 -0.436 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 22.0 Cg_exo -65.14 135.81 45.18 Favored 'Trans proline' 0 C--N 1.342 0.221 0 C-N-CA 122.804 2.336 . . . . 0.0 112.754 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.452 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 1.3 pt-20 -115.67 56.78 0.75 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.998 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.505 ' OH ' ' HA ' ' B' ' 11' ' ' VAL . 51.3 t80 -160.7 154.3 22.25 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.149 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.3 p90 . . . . . 0 C--O 1.253 1.285 0 CA-C-O 117.655 -1.164 . . . . 0.0 108.844 179.546 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.476 0.861 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . -168.69 -113.17 0.28 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 19.6 mt -75.4 65.09 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.153 0.502 . . . . 0.0 110.371 179.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.92 -40.88 2.33 Favored Glycine 0 C--N 1.33 0.203 0 CA-C-N 116.009 -0.542 . . . . 0.0 112.971 -179.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.707 ' HB ' HG12 ' B' ' 17' ' ' ILE . 1.0 OUTLIER -67.01 135.5 94.05 Favored Pre-proline 0 C--N 1.317 -0.84 0 CA-C-O 121.158 0.504 . . . . 0.0 112.097 -179.678 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.55 -25.0 41.38 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 123.238 2.625 . . . . 0.0 112.314 -179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.707 HG12 ' HB ' ' B' ' 15' ' ' THR . 28.8 pt -58.84 158.16 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 111.826 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -79.65 168.74 18.96 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.386 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -136.09 177.41 7.86 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.421 -179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.431 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 55.0 p90 -163.99 163.67 23.35 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.875 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.037 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.246 -179.732 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.787 -0.125 . . . . 0.0 112.787 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -163.42 -126.99 0.85 Allowed Glycine 0 CA--C 1.504 -0.639 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.77 134.76 37.01 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.44 -144.32 5.8 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.42 -0.895 . . . . 0.0 112.377 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 64.6 m80 -129.69 -42.41 1.29 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.671 0.272 . . . . 0.0 111.014 -179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 20.9 t -89.63 126.73 57.03 Favored Pre-proline 0 C--N 1.325 -0.462 0 N-CA-C 110.02 -0.363 . . . . 0.0 110.02 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.0 Cg_exo -67.77 140.22 50.4 Favored 'Trans proline' 0 CA--C 1.529 0.227 0 C-N-CA 122.904 2.403 . . . . 0.0 112.949 -179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.431 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 49.9 mt-10 -83.49 53.11 2.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.346 0.593 . . . . 0.0 110.071 178.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.7 t80 -160.83 154.79 22.66 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.942 -179.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 . . . . . 0 C--O 1.245 0.843 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.063 179.639 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' B' ' 16' ' ' PRO . 12.3 p . . . . . 0 N--CA 1.479 0.977 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . 0.403 ' H ' ' HA ' ' B' ' 16' ' ' PRO . . . 71.65 -120.39 8.15 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.678 -179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 9.6 tp -61.62 144.32 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.083 0.468 . . . . 0.0 111.4 -179.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.74 -57.73 5.04 Favored Glycine 0 N--CA 1.451 -0.313 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.398 -179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 25.1 m -157.5 113.53 1.87 Allowed Pre-proline 0 C--N 1.315 -0.895 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.468 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 26.6 Cg_exo -63.34 -55.49 0.73 Allowed 'Trans proline' 0 C--N 1.344 0.321 0 C-N-CA 122.882 2.388 . . . . 0.0 112.315 -179.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 6.1 tt -71.9 137.87 22.76 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 121.337 0.589 . . . . 0.0 110.846 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.4 p -161.79 -167.6 1.73 Allowed 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.339 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 50.7 m-85 -138.21 177.86 7.56 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.999 0.428 . . . . 0.0 110.552 -179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.436 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.7 p90 -162.0 163.57 28.8 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.289 -0.869 . . . . 0.0 109.79 179.122 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.416 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.709 0 CA-C-O 118.91 -0.939 . . . . 0.0 112.14 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.467 0 N-CA-C 112.595 -0.202 . . . . 0.0 112.595 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.9 -126.43 0.83 Allowed Glycine 0 CA--C 1.503 -0.662 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.31 133.0 42.57 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.05 -141.85 4.62 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.633 -0.794 . . . . 0.0 112.096 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.416 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.1 m80 -132.77 -46.42 0.87 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.773 0.286 . . . . 0.0 111.074 -179.813 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.4 t -86.45 126.43 64.41 Favored Pre-proline 0 C--N 1.325 -0.464 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 -179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 20.9 Cg_exo -65.93 137.6 49.53 Favored 'Trans proline' 0 CA--C 1.528 0.213 0 C-N-CA 122.729 2.286 . . . . 0.0 113.02 -179.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.436 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 46.1 mt-10 -80.43 58.01 3.02 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.767 -0.652 . . . . 0.0 110.449 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -79.99 154.66 28.08 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.526 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.5 p90 . . . . . 0 C--O 1.251 1.18 0 CA-C-O 117.547 -1.216 . . . . 0.0 109.382 179.605 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.652 ' N ' ' HG ' ' B' ' 18' ' ' SER . 35.9 m . . . . . 0 N--CA 1.481 1.108 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.23 -145.17 37.28 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.117 -0.563 . . . . 0.0 112.646 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 18.4 pt -83.35 52.78 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-O 120.923 0.392 . . . . 0.0 111.919 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -161.29 -128.79 0.97 Allowed Glycine 0 N--CA 1.439 -1.107 0 C-N-CA 120.71 -0.757 . . . . 0.0 111.743 179.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 21.2 p -82.4 133.7 49.71 Favored Pre-proline 0 C--N 1.315 -0.922 0 CA-C-O 120.573 0.225 . . . . 0.0 111.235 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.66 -53.07 3.64 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.477 2.118 . . . . 0.0 110.82 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 20.5 mt -75.42 141.48 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . 0.652 ' HG ' ' N ' ' B' ' 11' ' ' VAL . 0.6 OUTLIER -161.51 -163.28 0.97 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.72 -179.401 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -137.88 179.45 6.42 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.906 0.384 . . . . 0.0 110.567 -179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.569 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.2 p90 -162.88 163.1 26.56 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.947 178.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.661 0 CA-C-O 118.99 -0.894 . . . . 0.0 112.176 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.587 ' HA2' HG22 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.753 -0.139 . . . . 0.0 112.753 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.46 -128.06 0.94 Allowed Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.84 132.97 40.71 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 178.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.18 -143.04 5.2 Favored Glycine 0 N--CA 1.448 -0.522 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.179 -179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.6 m80 -132.08 -45.61 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.736 0.268 . . . . 0.0 111.077 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.484 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 24.1 t -85.75 125.38 69.15 Favored Pre-proline 0 C--N 1.326 -0.446 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 18.8 Cg_exo -66.74 140.3 55.57 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.992 2.461 . . . . 0.0 113.351 -178.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.569 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 49.2 mt-10 -83.58 55.82 3.36 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.089 178.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.8 t80 -160.95 157.81 27.04 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.371 -0.832 . . . . 0.0 109.967 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.1 t80 . . . . . 0 C--O 1.251 1.166 0 CA-C-O 117.403 -1.284 . . . . 0.0 108.542 179.591 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' B' ' 16' ' ' PRO . 18.9 m . . . . . 0 N--CA 1.477 0.911 0 CA-C-O 120.645 0.259 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.4 -132.54 12.71 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.849 -179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 16.1 tt -66.5 149.1 11.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.048 0.451 . . . . 0.0 111.601 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.21 -54.42 4.87 Favored Glycine 0 N--CA 1.452 -0.244 0 CA-C-N 115.993 -0.548 . . . . 0.0 112.442 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 83.2 m -157.98 119.99 2.02 Favored Pre-proline 0 C--N 1.313 -1.0 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.477 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 34.8 Cg_endo -66.15 -36.03 30.66 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.731 2.288 . . . . 0.0 112.291 -179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.424 ' H ' HG13 ' B' ' 17' ' ' ILE . 6.1 mt -64.92 161.61 2.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.059 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.3 p -79.34 -165.8 0.84 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.127 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -135.25 -179.83 5.87 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.17 0.51 . . . . 0.0 111.122 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.727 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 0.3 OUTLIER -159.58 163.86 34.71 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.479 178.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.698 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.385 -179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.498 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.52 -129.3 1.07 Allowed Glycine 0 CA--C 1.503 -0.688 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.12 134.58 39.94 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.19 -142.25 4.84 Favored Glycine 0 N--CA 1.447 -0.615 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.964 -179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.422 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.2 m80 -132.84 -45.14 0.87 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.775 0.287 . . . . 0.0 111.124 -179.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.507 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 30.0 t -92.78 127.23 48.68 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 116.641 -0.254 . . . . 0.0 110.41 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 25.5 Cg_exo -62.76 142.4 88.89 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.928 2.419 . . . . 0.0 112.55 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.727 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 43.4 mt-10 -80.11 56.38 2.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.313 0.578 . . . . 0.0 110.901 179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -79.14 151.87 31.07 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.386 -0.824 . . . . 0.0 111.289 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.9 t80 . . . . . 0 C--O 1.251 1.158 0 CA-C-O 117.388 -1.292 . . . . 0.0 108.576 -179.918 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.694 ' N ' ' HG1' ' B' ' 15' ' ' THR . 20.6 m . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 74.31 -71.87 1.47 Allowed Glycine 0 N--CA 1.453 -0.218 0 N-CA-C 111.827 -0.509 . . . . 0.0 111.827 -178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 50.4 mm -77.68 117.83 23.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 178.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 62.35 21.36 62.07 Favored Glycine 0 C--O 1.226 -0.35 0 CA-C-N 115.966 -0.561 . . . . 0.0 113.451 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.694 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 0.2 OUTLIER -161.1 122.24 1.65 Allowed Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 116.605 0.203 . . . . 0.0 110.56 179.561 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 39.3 Cg_exo -60.85 -44.19 26.88 Favored 'Trans proline' 0 C--N 1.343 0.277 0 C-N-CA 122.64 2.227 . . . . 0.0 111.935 -179.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.456 ' O ' ' HA ' ' B' ' 11' ' ' VAL . 41.0 pt -67.08 139.18 21.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.774 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . 0.5 ' HA ' ' HB ' ' B' ' 11' ' ' VAL . 3.0 p -158.49 -167.81 2.26 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.179 -179.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -140.58 174.62 10.34 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.001 0.429 . . . . 0.0 110.717 -179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.445 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.7 p90 -162.94 163.65 26.15 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.586 179.083 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.738 0 CA-C-O 118.878 -0.957 . . . . 0.0 112.17 -179.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.443 -0.263 . . . . 0.0 112.443 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.74 -126.01 0.8 Allowed Glycine 0 CA--C 1.502 -0.735 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.19 136.06 35.17 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 109.614 -0.514 . . . . 0.0 109.614 178.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.58 4.83 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.16 -179.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.415 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.0 m80 -129.83 -45.96 1.16 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.7 0.286 . . . . 0.0 110.984 -179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.6 t -87.4 125.97 63.85 Favored Pre-proline 0 C--N 1.326 -0.448 0 N-CA-C 110.125 -0.324 . . . . 0.0 110.125 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -68.16 138.33 43.14 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.666 2.244 . . . . 0.0 113.135 -179.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.9 mt-10 -81.47 58.22 3.59 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.051 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 43.5 t80 -79.68 154.55 28.54 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.623 -179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.4 p90 . . . . . 0 C--O 1.252 1.184 0 CA-C-O 117.485 -1.245 . . . . 0.0 109.377 179.676 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.478 0.958 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.85 -134.89 3.19 Favored Glycine 0 N--CA 1.444 -0.803 0 N-CA-C 111.526 -0.63 . . . . 0.0 111.526 -179.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.908 HD13 ' H ' ' B' ' 13' ' ' ILE . 0.2 OUTLIER -77.3 58.65 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.346 0.593 . . . . 0.0 111.014 179.345 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.0 -25.18 27.98 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.045 -179.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.452 ' HB ' ' HE1' ' B' ' 19' ' ' PHE . 8.3 p -66.54 122.22 80.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 CA-C-O 120.998 0.428 . . . . 0.0 111.572 -179.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 16.6 Cg_exo -67.98 -52.36 0.52 Allowed 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.89 2.393 . . . . 0.0 111.998 -179.567 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.658 ' HB ' ' CE1' ' A' ' 9' ' ' TYR . 39.9 pt -74.24 162.28 4.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.659 179.491 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -88.53 157.46 18.61 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.454 0.645 . . . . 0.0 112.074 -179.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.452 ' HE1' ' HB ' ' B' ' 15' ' ' THR . 75.6 m-85 -141.39 176.09 9.14 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.297 -179.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.457 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 47.4 p90 -161.64 163.89 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.46 178.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.021 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.392 -179.783 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.387 -0.285 . . . . 0.0 112.387 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -162.69 -129.65 1.05 Allowed Glycine 0 CA--C 1.503 -0.683 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 -179.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.45 132.81 45.31 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 178.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.44 -141.88 4.28 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.623 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 70.8 m80 -131.51 -45.97 0.98 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.923 0.361 . . . . 0.0 111.134 -179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.421 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -92.24 126.58 52.32 Favored Pre-proline 0 C--N 1.326 -0.449 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 26.2 Cg_exo -62.84 141.5 84.95 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.746 2.298 . . . . 0.0 112.568 -179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.457 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 50.8 mt-10 -80.0 54.88 1.99 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.077 0.465 . . . . 0.0 110.742 179.371 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.658 ' CE1' ' HB ' ' B' ' 17' ' ' ILE . 62.6 m-85 -143.25 155.18 44.43 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.984 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 8.5 p90 . . . . . 0 C--O 1.252 1.193 0 CA-C-O 117.447 -1.263 . . . . 0.0 109.207 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.704 ' N ' ' HG1' ' B' ' 15' ' ' THR . 57.3 t . . . . . 0 N--CA 1.48 1.044 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 69.37 -85.71 0.25 Allowed Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 51.3 mm -72.85 125.81 32.35 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 178.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 67.64 39.85 90.49 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.26 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.704 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 55.5 m -154.18 120.42 2.79 Favored Pre-proline 0 C--N 1.319 -0.752 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.483 ' HB2' ' H ' ' B' ' 17' ' ' ILE . 85.4 Cg_endo -83.16 -138.81 0.02 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.455 0 C-N-CA 122.753 2.302 . . . . 0.0 112.302 -179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.483 ' H ' ' HB2' ' B' ' 16' ' ' PRO . 32.3 pt -58.95 135.61 23.28 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 121.046 0.45 . . . . 0.0 110.48 179.384 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.6 p -160.24 -159.95 0.75 Allowed 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.394 -178.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -129.49 178.25 6.61 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.212 0.529 . . . . 0.0 111.449 -178.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.571 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 1.8 p90 -157.34 163.27 38.83 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.52 178.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.433 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.688 -1.062 . . . . 0.0 112.453 -179.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.583 ' O ' ' HA ' ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.446 -0.694 0 N-CA-C 111.501 -0.64 . . . . 0.0 111.501 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.49 -132.58 1.7 Allowed Glycine 0 N--CA 1.446 -0.654 0 N-CA-C 111.423 -0.671 . . . . 0.0 111.423 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.37 135.24 34.78 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 178.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.95 -142.19 4.53 Favored Glycine 0 N--CA 1.447 -0.625 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.052 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.433 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 69.9 m80 -131.74 -43.88 0.99 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.734 0.267 . . . . 0.0 111.114 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 35.3 t -93.28 127.66 45.89 Favored Pre-proline 0 C--N 1.325 -0.48 0 CA-C-N 116.681 -0.236 . . . . 0.0 110.391 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.448 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 25.2 Cg_exo -62.67 140.11 79.03 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.849 2.366 . . . . 0.0 112.311 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.571 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 7.3 mt-10 -80.79 56.92 2.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.305 0.574 . . . . 0.0 110.812 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -79.58 150.93 30.91 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.029 179.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 18.3 t80 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.983 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 10.2 p . . . . . 0 N--CA 1.48 1.072 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 79.25 -61.95 4.1 Favored Glycine 0 C--O 1.227 -0.295 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -177.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 41.4 mm -82.09 155.39 4.03 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -53.44 -36.55 53.81 Favored Glycine 0 C--N 1.331 0.303 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.987 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 2.4 p -73.41 144.96 84.64 Favored Pre-proline 0 C--N 1.319 -0.748 0 CA-C-O 120.95 0.405 . . . . 0.0 110.922 179.333 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -70.85 44.27 0.5 Allowed 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 123.176 2.584 . . . . 0.0 113.282 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.49 HG21 ' CD1' ' A' ' 9' ' ' TYR . 40.5 pt -61.16 143.38 14.94 Favored 'Isoleucine or valine' 0 C--O 1.237 0.44 0 CA-C-O 120.98 0.419 . . . . 0.0 110.873 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . 0.426 ' HB2' ' H ' ' B' ' 19' ' ' PHE . 1.4 p -159.05 -153.68 0.38 Allowed 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.571 -0.741 . . . . 0.0 109.89 -178.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.426 ' H ' ' HB2' ' B' ' 18' ' ' SER . 34.5 m-85 -130.4 168.13 17.45 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.874 0.369 . . . . 0.0 111.006 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -153.2 162.87 40.82 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.963 178.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.442 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.246 0.896 0 CA-C-O 118.704 -1.054 . . . . 0.0 112.22 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.523 0 N-CA-C 111.859 -0.496 . . . . 0.0 111.859 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 178.84 -126.89 1.09 Allowed Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 111.238 -0.745 . . . . 0.0 111.238 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -93.25 131.87 37.96 Favored 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -175.85 -140.19 3.37 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.316 -0.945 . . . . 0.0 112.43 -179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.442 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 64.5 m80 -131.36 -43.25 1.04 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.594 0.235 . . . . 0.0 111.201 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.441 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 19.9 t -85.63 126.38 66.54 Favored Pre-proline 0 C--N 1.326 -0.425 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.441 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 13.4 Cg_exo -70.09 128.45 15.74 Favored 'Trans proline' 0 CA--C 1.529 0.258 0 C-N-CA 122.7 2.267 . . . . 0.0 113.536 -178.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -105.8 75.73 1.14 Allowed 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 177.447 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.49 ' CD1' HG21 ' B' ' 17' ' ' ILE . 68.4 t80 -77.21 154.58 32.93 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.553 -1.203 . . . . 0.0 110.951 -178.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.7 t80 . . . . . 0 C--O 1.245 0.825 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.412 179.905 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.764 ' N ' ' HG1' ' B' ' 15' ' ' THR . 31.3 t . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 71.99 -118.7 7.05 Favored Glycine 0 N--CA 1.448 -0.52 0 C-N-CA 120.495 -0.86 . . . . 0.0 111.696 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.678 HD13 ' H ' ' B' ' 13' ' ' ILE . 0.2 OUTLIER -62.92 136.32 26.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-O 120.974 0.416 . . . . 0.0 110.668 179.333 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 68.41 35.73 82.55 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.987 -0.625 . . . . 0.0 112.299 -179.41 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.764 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 73.4 m -156.55 126.81 3.37 Favored Pre-proline 0 C--N 1.32 -0.691 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_endo -82.34 -148.91 0.04 OUTLIER 'Trans proline' 0 N--CA 1.459 -0.513 0 C-N-CA 122.479 2.119 . . . . 0.0 111.793 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 tt -66.33 139.92 20.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.245 0.545 . . . . 0.0 110.494 179.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.7 p -157.74 -168.54 2.57 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.517 -179.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -137.19 179.54 6.33 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.081 0.467 . . . . 0.0 110.822 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.438 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.8 p90 -164.12 163.55 23.03 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.677 179.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.414 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.243 0.693 0 CA-C-O 118.962 -0.91 . . . . 0.0 112.191 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 120.479 -0.067 . . . . 0.0 112.961 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.3 -128.71 1.07 Allowed Glycine 0 N--CA 1.448 -0.542 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.68 134.77 39.15 Favored 'General case' 0 C--N 1.313 -0.98 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 178.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 179.48 -141.56 4.82 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.6 -0.81 . . . . 0.0 112.083 -179.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.414 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 70.7 m80 -132.52 -45.94 0.89 Allowed 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.662 0.268 . . . . 0.0 111.057 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.4 t -86.63 127.33 60.89 Favored Pre-proline 0 C--N 1.325 -0.475 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -67.02 139.72 52.05 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.767 2.312 . . . . 0.0 112.895 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.438 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.0 mt-10 -81.15 55.3 2.48 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.251 0.548 . . . . 0.0 110.489 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -160.92 156.5 25.01 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.994 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--O 1.246 0.909 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 179.665 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.783 ' N ' ' HG1' ' B' ' 15' ' ' THR . 45.7 t . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 72.12 -119.59 7.43 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.404 -0.903 . . . . 0.0 111.106 -178.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 27.7 pt -65.46 138.17 23.6 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 CA-C-O 120.822 0.344 . . . . 0.0 110.48 178.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 71.39 39.61 61.37 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.257 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.783 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 88.2 m -156.27 126.29 3.3 Favored Pre-proline 0 C--N 1.32 -0.707 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' B' ' 15' ' ' THR . 17.2 Cg_exo -67.22 111.76 2.35 Favored 'Trans proline' 0 C--N 1.343 0.281 0 C-N-CA 122.555 2.17 . . . . 0.0 111.889 -179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.7 pt -87.18 138.87 18.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.834 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.8 p -81.51 -173.74 4.56 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.87 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.7 m-85 -137.99 178.67 6.94 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.041 0.448 . . . . 0.0 110.8 -179.224 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.449 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 54.8 p90 -164.29 160.83 21.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.24 -0.891 . . . . 0.0 109.831 179.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.531 -1.149 . . . . 0.0 112.453 -179.871 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.353 0 N-CA-C 112.668 -0.173 . . . . 0.0 112.668 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.75 -128.35 0.99 Allowed Glycine 0 CA--C 1.504 -0.64 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -179.582 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.4 133.72 41.1 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 178.38 -143.83 6.13 Favored Glycine 0 N--CA 1.448 -0.521 0 C-N-CA 120.762 -0.732 . . . . 0.0 111.902 -179.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 54.4 m-70 -132.17 -44.33 0.94 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.862 0.331 . . . . 0.0 110.951 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.5 t -85.27 126.13 68.08 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo -67.49 139.68 49.9 Favored 'Trans proline' 0 C--O 1.232 0.224 0 C-N-CA 122.867 2.378 . . . . 0.0 112.964 -179.194 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.449 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 48.7 mt-10 -82.56 58.32 4.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.231 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 t80 -158.58 160.68 36.87 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.287 -179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 25.3 t80 . . . . . 0 C--O 1.246 0.884 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 179.818 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.68 HG13 ' HA2' ' A' ' 1' ' ' GLY . 30.4 m . . . . . 0 N--CA 1.482 1.16 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.53 -164.58 38.08 Favored Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.654 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 14.7 tt -80.28 60.29 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.61 0 CA-C-O 122.235 1.017 . . . . 0.0 110.881 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 168.41 -115.19 0.6 Allowed Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.559 ' N ' ' HD3' ' B' ' 16' ' ' PRO . 4.5 m -148.91 56.48 2.49 Favored Pre-proline 0 C--N 1.318 -0.765 0 CA-C-O 121.013 0.435 . . . . 0.0 110.538 179.042 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' B' ' 15' ' ' THR . 5.7 Cg_exo -79.92 127.99 7.27 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 122.591 2.194 . . . . 0.0 111.819 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.4 pt -62.09 146.12 12.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.917 179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . 0.673 ' HG ' ' N ' ' B' ' 11' ' ' VAL . 0.7 OUTLIER -160.29 -174.34 4.47 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.689 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -135.02 -177.69 4.75 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.048 0.451 . . . . 0.0 110.687 -178.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.445 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 53.8 p90 -162.99 163.56 26.04 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.842 179.063 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.412 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.66 -1.078 . . . . 0.0 112.205 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.68 ' HA2' HG13 ' B' ' 11' ' ' VAL . . . . . . . . 0 N--CA 1.45 -0.433 0 N-CA-C 112.952 -0.059 . . . . 0.0 112.952 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.62 -127.44 0.92 Allowed Glycine 0 CA--C 1.503 -0.667 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.17 132.62 42.38 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -179.34 -142.3 4.9 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.141 -179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.412 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.3 m80 -133.12 -45.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.708 0.289 . . . . 0.0 111.126 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.0 t -85.91 126.11 66.65 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 21.0 Cg_exo -65.77 139.08 56.05 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.823 2.349 . . . . 0.0 112.987 -179.224 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.445 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 47.1 mt-10 -81.77 56.37 3.02 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.477 178.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 47.0 t80 -160.76 156.97 26.11 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.11 -179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 22.2 t80 . . . . . 0 C--O 1.246 0.883 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 179.689 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 42.9 t . . . . . 0 N--CA 1.482 1.149 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 76.65 -83.41 1.02 Allowed Glycine 0 N--CA 1.451 -0.333 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 -178.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . 0.804 HD13 ' H ' ' B' ' 13' ' ' ILE . 0.2 OUTLIER -84.06 140.52 16.04 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 177.64 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -75.21 -46.84 14.46 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.623 -0.799 . . . . 0.0 112.173 -179.195 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.11 137.44 53.15 Favored Pre-proline 0 C--N 1.315 -0.892 0 CA-C-N 115.362 -0.419 . . . . 0.0 111.127 179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.13 101.24 0.69 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.633 2.222 . . . . 0.0 112.819 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.428 ' HB ' ' CD1' ' A' ' 9' ' ' TYR . 10.3 tt -73.16 147.03 10.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.614 179.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 2.3 p -153.17 -170.65 3.68 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.554 -179.851 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.4 m-85 -138.07 172.51 12.82 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.984 0.421 . . . . 0.0 111.066 -179.073 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.475 ' CD2' ' HB3' ' A' ' 8' ' ' GLU . 47.4 p90 -155.28 163.85 39.58 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.862 178.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.244 0.721 0 CA-C-O 118.924 -0.931 . . . . 0.0 112.28 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.63 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.56 -128.72 1.16 Allowed Glycine 0 CA--C 1.505 -0.54 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -92.25 133.92 35.38 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 178.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -177.2 -140.35 3.62 Favored Glycine 0 N--CA 1.448 -0.555 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.368 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.407 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 67.2 m80 -130.29 -44.36 1.14 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.562 0.22 . . . . 0.0 111.176 -179.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.453 ' HA ' ' HD3' ' A' ' 7' ' ' PRO . 21.8 t -84.82 126.3 68.69 Favored Pre-proline 0 C--N 1.326 -0.443 0 N-CA-C 110.136 -0.32 . . . . 0.0 110.136 -179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 6' ' ' VAL . 17.1 Cg_exo -67.24 128.23 18.09 Favored 'Trans proline' 0 CA--C 1.528 0.201 0 C-N-CA 122.649 2.233 . . . . 0.0 113.009 -179.175 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.475 ' HB3' ' CD2' ' B' ' 20' ' ' TYR . 2.9 pt-20 -112.85 61.54 0.64 Allowed 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.932 178.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.428 ' CD1' ' HB ' ' B' ' 17' ' ' ILE . 29.9 t80 -79.38 157.03 27.69 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.336 -179.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.245 0.835 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.365 -179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . . . . . . . . . 31.2 m . . . . . 0 N--CA 1.481 1.094 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 173.72 -147.95 9.8 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 111.523 -0.631 . . . . 0.0 111.523 -179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 15.7 pt -76.64 127.34 37.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 120.921 0.391 . . . . 0.0 110.819 179.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . -85.93 39.52 3.03 Favored Glycine 0 N--CA 1.453 -0.212 0 C-N-CA 121.045 -0.597 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . . . . . . . . . 12.3 p -85.88 128.58 57.76 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.748 -0.226 . . . . 0.0 111.041 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -74.49 54.1 3.29 Favored 'Trans proline' 0 CA--C 1.531 0.358 0 C-N-CA 123.055 2.504 . . . . 0.0 112.598 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.4 HD12 ' HB2' ' A' ' 9' ' ' TYR . 38.8 mm -70.32 146.63 12.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.51 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p -145.55 -163.33 1.7 Allowed 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.059 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -133.49 177.82 7.4 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.226 0.536 . . . . 0.0 111.491 -178.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.552 ' CD2' ' HG2' ' A' ' 8' ' ' GLU . 2.9 p90 -158.6 162.45 37.33 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 114.975 -1.011 . . . . 0.0 109.539 178.812 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . 0.426 ' C ' ' HD1' ' A' ' 5' ' ' HIS . . . . . . . . 0 C--O 1.248 0.983 0 CA-C-O 118.749 -1.028 . . . . 0.0 112.399 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.646 0 N-CA-C 111.506 -0.637 . . . . 0.0 111.506 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.81 -131.85 1.55 Allowed Glycine 0 N--CA 1.446 -0.659 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.22 134.88 34.13 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 178.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.73 -142.71 4.95 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.509 -0.853 . . . . 0.0 112.178 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . 0.426 ' HD1' ' C ' ' B' ' 21' ' ' GLY . 68.1 m80 -130.05 -44.73 1.16 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.722 0.261 . . . . 0.0 111.154 -179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' B' ' 20' ' ' TYR . 27.3 t -89.91 126.04 58.74 Favored Pre-proline 0 C--N 1.326 -0.416 0 N-CA-C 110.232 -0.285 . . . . 0.0 110.232 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_endo -65.53 138.95 56.72 Favored 'Trans proline' 0 C--O 1.232 0.216 0 C-N-CA 122.81 2.34 . . . . 0.0 112.851 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.552 ' HG2' ' CD2' ' B' ' 20' ' ' TYR . 4.2 mt-10 -84.02 55.3 3.24 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.243 0.544 . . . . 0.0 110.109 179.619 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.4 ' HB2' HD12 ' B' ' 17' ' ' ILE . 45.9 t80 -160.7 157.64 27.38 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.13 -179.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 23.6 t80 . . . . . 0 C--O 1.25 1.126 0 CA-C-O 117.381 -1.295 . . . . 0.0 108.498 179.635 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' VAL . . . . . 0.661 ' N ' ' HG1' ' B' ' 15' ' ' THR . 7.4 m . . . . . 0 N--CA 1.481 1.091 0 CA-C-O 121.126 0.489 . . . . 0.0 111.051 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' GLY . . . . . . . . . . . . . . . 78.4 -62.86 3.73 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.965 -0.562 . . . . 0.0 112.098 -179.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' ILE . . . . . . . . . . . . . 49.4 mm -79.01 120.86 31.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' GLY . . . . . . . . . . . . . . . 74.57 -62.55 2.32 Favored Glycine 0 C--O 1.229 -0.19 0 CA-C-N 116.087 -0.506 . . . . 0.0 112.793 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' THR . . . . . 0.661 ' HG1' ' N ' ' B' ' 11' ' ' VAL . 6.3 p -99.15 120.65 57.74 Favored Pre-proline 0 C--N 1.316 -0.881 0 N-CA-C 110.369 -0.234 . . . . 0.0 110.369 179.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -62.7 -49.52 5.37 Favored 'Trans proline' 0 CA--C 1.529 0.255 0 C-N-CA 122.443 2.095 . . . . 0.0 112.412 -179.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 12.8 tt -66.76 142.9 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 121.532 0.682 . . . . 0.0 111.679 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' SER . . . . . . . . . . . . . 1.9 p -98.94 -171.69 2.14 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 115.233 -0.894 . . . . 0.0 111.111 -179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -138.95 176.23 8.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 120.879 0.371 . . . . 0.0 110.55 -179.371 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' TYR . . . . . 0.452 ' HD2' ' HG2' ' A' ' 8' ' ' GLU . 50.5 p90 -161.87 164.79 28.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.845 179.393 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.03 0 CA-C-O 118.754 -1.025 . . . . 0.0 112.374 -179.975 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.395 0 N-CA-C 112.551 -0.22 . . . . 0.0 112.551 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -166.29 -128.46 0.97 Allowed Glycine 0 CA--C 1.503 -0.694 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -179.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.18 135.64 41.06 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 178.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.96 -141.97 4.66 Favored Glycine 0 N--CA 1.447 -0.571 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.069 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 66.6 m80 -132.85 -44.23 0.88 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 120.74 0.305 . . . . 0.0 111.026 -179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.7 t -91.73 126.63 53.21 Favored Pre-proline 0 C--N 1.325 -0.488 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.419 ' HG2' ' CD2' ' A' ' 9' ' ' TYR . 22.9 Cg_endo -62.94 141.42 84.12 Favored 'Trans proline' 0 C--O 1.233 0.255 0 C-N-CA 122.683 2.255 . . . . 0.0 112.752 -179.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . 0.452 ' HG2' ' HD2' ' B' ' 20' ' ' TYR . 41.7 mt-10 -79.57 62.11 3.77 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.453 0.644 . . . . 0.0 110.684 179.498 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.419 ' CD2' ' HG2' ' A' ' 7' ' ' PRO . 0.3 OUTLIER -78.36 151.97 32.57 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.009 -179.929 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 21.0 t80 . . . . . 0 C--O 1.248 0.979 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 -179.999 . . . . . . . . 0 0 . 1 stop_ save_